Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
5.850
+3.810 (+186.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
81,892,619
Open
7.030
Bid (Size)
5.390 (7)
Ask (Size)
5.400 (4)
Prev. Close
2.040
Today's Range
5.720 - 15.06
52wk Range
1.835 - 45.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Today 14:37 EDT
Via
Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Today 13:37 EDT
Via
Benzinga
Performance
YTD
-36.41%
-36.41%
1 Month
+57.26%
+57.26%
3 Month
-7.66%
-7.66%
6 Month
-35.00%
-35.00%
1 Year
-86.83%
-86.83%
More News
Read More
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Today 12:28 EDT
Via
Benzinga
Exposures
Fossil Fuels
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Today 11:50 EDT
Via
PressReach
Exposures
Product Safety
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
Today 9:56 EDT
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Today 9:41 EDT
Via
Benzinga
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Today 8:00 EDT
From
Alzamend Neuro, Inc.
Via
Business Wire
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 12, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 12, 2024
Via
News Direct
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
August 06, 2024
Via
News Direct
Exposures
Product Safety
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
August 06, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
Via
PressReach
Exposures
Product Safety
Headline
August 06, 2024
Via
News Direct
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
Via
PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
August 05, 2024
Via
Benzinga
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 20, 2024
Via
Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.